Khalil, M. F., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Mileham, K. F., Ahn, E. R., … Schilsky, R. L. (2023). 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In Annals of Oncology (Vol. 34, pp. S265–S266). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2930

Khalil, M. F., M. Rothe, P. K. Mangat, E. Garrett-Mayer, K. F. Mileham, E. R. Ahn, H. L. Duvivier, et al. “207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In Annals of Oncology, 34:S265–66. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2930.

Khalil MF, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Ahn ER, et al. 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: Annals of Oncology. Elsevier BV; 2023. p. S265–6.

Khalil, M. F., et al. “207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S265–66. Crossref, doi:10.1016/j.annonc.2023.09.2930.

Khalil MF, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Ahn ER, Duvivier HL, Farrington LC, Akce M, Behl D, Gold PJ, Chiu VK, Vijayvergia N, Calfa C, Gaba A, Meric-Bernstam F, Schuetze SM, Gregory A, Halabi S, Schilsky RL. 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. Elsevier BV; 2023. p. S265–S266.